CTLA4 and neoplasm: Double combination of i.t. ISF35 with a systemic anti-PD-1 antibody without anti-CTLA-4 antibody, significantly inhibited tumor growth of both injected and uninjected tumor compared to either monotherapy (P < 0.05, unpaired t test; Supplementary Fig. 2b); however, in contrast to triple combination, dual combination was unable to cure the mice from tumor (Fig. 6c and Supplementary Fig. 2b).